Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Work In Process (2023 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Work In Process for 3 consecutive years, with $387000.0 as the latest value for Q3 2025.

  • Quarterly Work In Process fell 53.93% to $387000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $387000.0 through Sep 2025, down 53.93% year-over-year, with the annual reading at $1.2 million for FY2024, 13.22% up from the prior year.
  • Work In Process for Q3 2025 was $387000.0 at Rhythm Pharmaceuticals, down from $767000.0 in the prior quarter.
  • The five-year high for Work In Process was $3.5 million in Q3 2023, with the low at $387000.0 in Q3 2025.
  • Average Work In Process over 3 years is $1.7 million, with a median of $1.5 million recorded in 2024.
  • Peak annual rise in Work In Process hit 13.22% in 2024, while the deepest fall reached 75.99% in 2024.
  • Over 3 years, Work In Process stood at $1.1 million in 2023, then grew by 13.22% to $1.2 million in 2024, then crashed by 69.04% to $387000.0 in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $387000.0, $767000.0, and $1.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.